Safety Concerns Doom Addex's Lead ADX10059 On Eve of Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Elevated liver enzymes forced the Swiss biotech to halt a development of its lead compound in chronic indications, but the company insists a back-up shows promise.
You may also be interested in...
Addex Extends Its Runway With CHF 20 Million Investment By BVF
Last year's failure of GERD candidate ADX10059 enabled BVF to buy in at a value price, but Addex won't make mistake of focusing primarily on one asset again.
Addex Extends Its Runway With CHF 20 Million Investment By BVF
Last year's failure of GERD candidate ADX10059 enabled BVF to buy in at a value price, but Addex won't make mistake of focusing primarily on one asset again.
Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side Effect Therapy Into Phase II Testing
After a costly 2009 setback, venture philanthropy steps in to help Addex move a risky program forward.